Trial Profile
Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation: a Randomized, Positive-controlled, Phase 3 Study (EVIDENCE, CCTC-1501)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Icotinib (Primary) ; Cisplatin; Pemetrexed; Vinorelbine
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EVIDENCE
- Sponsors Betta Pharmaceuticals Co Ltd
- 14 Jul 2021 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 14 Jul 2021 Planned primary completion date changed from 1 Dec 2020 to 30 Jun 2022.
- 14 Jul 2021 Status changed from recruiting to active, no longer recruiting.